Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30+ Peripheral T-cell Lymphoma”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Large-scale testing (Phase 3)Study completedNCT01578499
What this trial is testing

Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Who this might be right for
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
Millennium Pharmaceuticals, Inc. 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Testing effectiveness (Phase 2)UnknownNCT05006664
What this trial is testing

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Who this might be right for
Lymphoma, T-Cell, Peripheral
Czech Lymphoma Study Group 33
Testing effectiveness (Phase 2)Study completedNCT01396070
What this trial is testing

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Who this might be right for
Non-Hodgkin Lymphoma (NHL)Cutaneous LymphomaCutaneous T-cell Lymphoma (CTCL)+2 more
Youn Kim 36
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Early research (Phase 1)Active Not RecruitingNCT04526834
What this trial is testing

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more
Tessa Therapeutics 21
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Testing effectiveness (Phase 2)Ended earlyNCT02499627
What this trial is testing

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 43
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Very early researchNot Yet RecruitingNCT07048353
What this trial is testing

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Who this might be right for
LymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd 15
Testing effectiveness (Phase 2)Study completedNCT04569032
What this trial is testing

Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Who this might be right for
Peripheral T-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 82
Not applicableLooking for participantsNCT07074457
What this trial is testing

Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

Who this might be right for
CD30+ Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University 47
Not applicableNo Longer AvailableNCT01196208
What this trial is testing

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin+1 more
Seagen Inc.
Testing effectiveness (Phase 2)Study completedNCT04074746
What this trial is testing

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
M.D. Anderson Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT02497131
What this trial is testing

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 25
Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04653649
What this trial is testing

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Who this might be right for
Hodgkin Lymphoma, AdultT Cell Lymphoma
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 30
Testing effectiveness (Phase 2)Ended earlyNCT03947255
What this trial is testing

Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Who this might be right for
Hodgkin LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell Lymphoma
Seagen Inc. 12
Early research (Phase 1)WithdrawnNCT03205891
What this trial is testing

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Who this might be right for
Malignant Neoplasms Stated as Primary Lymphoid HaematopoieticClassical Hodgkin LymphomaAnaplastic Large Cell Lymphoma+1 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT01777152
What this trial is testing

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Who this might be right for
Anaplastic Large-Cell LymphomaNon-Hodgkin LymphomaT-Cell Lymphoma
Seagen Inc. 452
Load More Results